Cooper Companies (NASDAQ:COO) Upgraded to “Hold” at Barclays

Barclays upgraded shares of Cooper Companies (NASDAQ:COO) to a hold rating in a report released on Wednesday morning,Zacks reports.

Several other analysts also recently commented on the stock. UBS Group decreased their price objective on shares of Cooper Companies from $75.00 to $66.00 and set a “neutral” rating on the stock in a research report on Thursday, September 10th. Citigroup reaffirmed a “neutral” rating and issued a $60.00 target price (down from $80.00) on shares of Cooper Companies in a report on Thursday, September 10th. Mizuho set a $75.00 price target on Cooper Companies and gave the stock an “outperform” rating in a research note on Thursday, September 10th. Zacks Research lowered Cooper Companies from a “hold” rating to a “strong sell” rating in a research note on Friday, September 11th. Finally, Bank of America reissued a “neutral” rating and set a $65.00 price target (down from $80.00) on shares of Cooper Companies in a report on Thursday, September 10th. Four analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $68.60.

Cooper Companies Trading Down 3.0%

Shares of NASDAQ:COO opened at $54.75 on Wednesday. The stock has a 50 day moving average of $66.00 and a 200 day moving average of $66.85. The company has a market cap of $10.41 billion, a PE ratio of 18.69, a price-to-earnings-growth ratio of 2.30 and a beta of 0.83. The company has a current ratio of 1.22, a quick ratio of 0.73 and a debt-to-equity ratio of 0.23. Cooper Companies has a 12-month low of $51.01 and a 12-month high of $89.83.

Cooper Companies (NASDAQ:COO) last released its earnings results on Wednesday, September 9th. The medical device company reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.12 by $0.03. Cooper Companies had a net margin of 13.46% and a return on equity of 10.90%. The company had revenue of $1.07 billion during the quarter, compared to analyst estimates of $1.10 billion. During the same period in the prior year, the firm posted $0.49 EPS. The firm’s quarterly revenue was up .5% compared to the same quarter last year. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. As a group, equities research analysts expect that Cooper Companies will post 4.53 EPS for the current year.

Cooper Companies announced that its board has initiated a stock repurchase plan on Wednesday, September 9th that authorizes the company to buyback $3.00 billion in outstanding shares. This buyback authorization authorizes the medical device company to buy up to 22.7% of its stock through open market purchases. Stock buyback plans are usually an indication that the company’s board of directors believes its stock is undervalued.

Insider Transactions at Cooper Companies

In related news, Director Lawrence Kurzius bought 10,000 shares of the stock in a transaction dated Monday, September 14th. The shares were purchased at an average price of $53.91 per share, with a total value of $539,100.00. Following the completion of the acquisition, the director owned 21,099 shares of the company’s stock, valued at $1,137,447.09. This represents a 90.10% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Paul Keel bought 4,701 shares of the company’s stock in a transaction that occurred on Friday, September 11th. The shares were bought at an average price of $53.18 per share, with a total value of $249,999.18. Following the transaction, the director owned 4,701 shares of the company’s stock, valued at $249,999.18. The trade was a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders have purchased 34,701 shares of company stock valued at $1,880,039. 2.08% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Envestnet Portfolio Solutions Inc. grew its position in shares of Cooper Companies by 112.8% during the second quarter. Envestnet Portfolio Solutions Inc. now owns 15,784 shares of the medical device company’s stock valued at $1,132,000 after purchasing an additional 8,366 shares in the last quarter. HBK Investments L P purchased a new stake in shares of Cooper Companies in the second quarter worth about $31,666,000. Sequoia Financial Advisors LLC lifted its position in shares of Cooper Companies by 290.4% in the second quarter. Sequoia Financial Advisors LLC now owns 34,286 shares of the medical device company’s stock worth $2,459,000 after buying an additional 25,504 shares in the last quarter. Tidal Investments LLC lifted its position in shares of Cooper Companies by 281.4% in the second quarter. Tidal Investments LLC now owns 82,903 shares of the medical device company’s stock worth $5,945,000 after buying an additional 61,165 shares in the last quarter. Finally, National Pension Service boosted its stake in Cooper Companies by 9,314.0% during the second quarter. National Pension Service now owns 526,149 shares of the medical device company’s stock valued at $37,730,000 after buying an additional 520,560 shares during the last quarter. Institutional investors own 24.39% of the company’s stock.

Key Cooper Companies News

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Director John Kurzius purchased 10,000 COO shares for approximately $539,100. The sizable open-market purchase may signal that the director believes the recent selloff has created attractive value. Cooper Companies Director Kurzius Buys 10,000 Shares
• Positive Sentiment: Recently appointed director Paul Keel bought approximately $250,000 of Cooper Companies stock, adding another insider-confidence signal amid the share-price weakness. Recently Appointed Cooper Companies Director Paul Keel Buys Stock
• Positive Sentiment: Director Rosebrough purchased 10,000 shares at a weighted average price of $54.16, a position representing roughly 92% of his previously reported equity holdings. The size relative to his prior holdings may be viewed as a strong personal commitment. Cooper Companies Director Rosebrough Buys Shares

Cooper Companies Company Profile

CooperCompanies (NASDAQ: COO) is a global medical device company focused on improving vision and advancing women’s health. Its operations are organized primarily through CooperVision and CooperSurgical, which develop, manufacture and distribute products for eye care, fertility and other areas of reproductive health.

CooperVision offers a broad range of contact lenses, including lenses for nearsightedness, farsightedness, astigmatism and presbyopia. Its portfolio includes daily disposable, reusable and specialty lenses, as well as products designed to address the progression of myopia in children and adolescents.